Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
RNS dropped
Exactly “Patent Cliffs" are a growing opportunity for much smaller bios, such as Sareum.
* The one to keep an eye on in particular is J&J‘s psoriasis treatment, Stelara, which has annual sales of over $7.5 billion and targets psoriasis, psoriatic arthritis and Crohn’s disease. Its patent appears be expiring in the next 2 years.
* The Stelara "patent cliff" is great news for Sareum, as SDC1801 is aimed at psoriasis (& other diseases).
* It's why many of us have been topping up with more SAR shares at these bargain basement prices over the last few weeks....
Good luck, Brighty
Can we expect a steady rise now ?
Brilliant. The 110k has been reported already, confirming to me RF have no more to sell, otherwise they would have continued to sell and report at the end of the day.
True, Potnak. But it'd make for a nice photo op and news headline at the conference, "Plucky Brits sign multi-zillion dollar deal". A spokesman for the company said, "now we can afford to replace the squeaky chairs".
Regards.
I don't think SAR would be attending if a deal was, already on the table. More likely that disscussions are progressing but data, us still needed so the Board will use the opportunity to talk to a wider audience. I also agree theat the board wouldn't be attending with out some to shout about.
Https://www.fiercepharma.com/special-report/top-15-blockbuster-patent-expirations-coming-decade
Actually, for all we know a deal has already been agreed pending certain key results in the data readout with a news blackout 'til then.
It's nice to dream.
Its been NT for me last 45 mins and it certainly looks like they are trying to deter buyers
Headline spread widened to 24-26 when in reality the bid price is 24.76 (with AJBells)
Hi Bailiff - if the results are top notch with low tox effects etc. plus the potential to jump ahead to P2a trials, I just hope whichever BoD member is there maximises the opportunity to speak with the big pharmas rather than the smaller biotechs.
I believe an RNS would have to be released if the options are taken up.
Regards
On the warrants and options. It woukd be good to know what the liability is on warrants for RF, HNWI and options for directors etc. If there was to be an RNS, id like to see all liabilities laid out. Get the skeletons out of the cupboard as it were.
Correct mathsprof, debt would have been clears as per last trance of shares issued in RNS.
I dare say RF have sold the entire caboodle at circa 200 to 300 per cent profit.
Options l agree they may well purchase and sell but hang on to for a bit as the price climbs.
The profit on the options will be tidy and will make them more money than the equity release.
That bad episode is behind us now thank f.
Regards
I think the debt was cleared at the point when SAR issued RF with the final batch of shares (from SAr's point of view). RF still had to sell them in the market. I think this has now happened. It remains to be seen what they will do with the warrants. However because this is effectively a free carry, they may well wait before they excercise them.
Silverfoil13 posted 3rd May
I asked SAR if the RF debt had been cleared and they confirmed yes it had.
I reckon RF have now sold their last 110k. We'll hear later if I'm right. Meanwhile I expect SP to rise quickly.
I managed to get 4000 but had to do 2x2000 trades!
Bloody annoying as am heading into meetings all day shortly
I went as low as 500 shares but still it went to NT
Maybe the BIO conference is also an opportune time for SAR to do the big reveal regarding 737?
@HBD. Good morning to you.
In answer to your question about whether Sar will have news before attending………
I can’t see why they would have booked to go unless they had something to shout about that was positive. I wouldn’t want to go to a public event with suspected bad news in my back pocket………
just to add, i searched the https://convention.bio.org/ site for sareum and it came back with 2 results - one for sareum ltd and another, maybe more interesting one:
https://convention.bio.org/speakers/martin-gouldstone
"...he was previously a partner at results healthcare, where he co-led the healthcare practice;head of lifesciences in the uk for bdo, the lead for the m&a process in europe for *****iles, and business development and licensing lead at confirmant, pharmacopeia, sareum. he has extensive experience buying and selling multi-billion dollar deals across europe and the us and negotiating multi-year research partnerships."
sounds like he's a handy contact to have in your little black book.
I see the events page on the SAR website has been updated.
https://sareum.com/events/
Question is, will we have news on the outcome of the 1801 trial before the start of June?
Please excuse my ‘senior moment’ post below. How I missed that HYR RNS after scanning about four times, I’ll never know 😂
Hi Desamax
The half year report appears to have been issued on 28th March 2024, according to the RNS.